Lymphoma Trial, Recruiting (NCT06795113)

Lymphoma Trial, Recruiting NCT06795113 Sponsor: Ruijin Hospital Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT06795113 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with a type of lymphoma (a cancer of the lymphatic system) that is confirmed by laboratory testing of tissue samples and is classified as "high-metabolic" (meaning it shows high activity on certain scans)
People who have had a specific type of scan called a PET/CT scan (which uses a special tracer to detect cancer activity) done before, during, and after their cancer treatment
People who were treated with a standard first-line treatment plan for lymphoma, chosen according to accepted medical guidelines and their individual circumstances
People who have complete medical records and follow-up information available

Who may not be able to join:

People who have previously received any cancer treatment before the current lymphoma diagnosis
People who have a history of any other type of cancer
People whose medical records or scan images are incomplete or missing
People who currently have another active cancer at the same time as their lymphoma

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 13361860108

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06795113

Sponsor: Ruijin Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Lymphoma

Trial contact: 13361860108

More information: https://clinicaltrials.gov/study/NCT06795113

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with a type of lymphoma (a cancer of the lymphatic system) that is confirmed by laboratory testing of tissue samples and is classified as "high-metabolic" (meaning it shows high activity on certain scans)
People who have had a specific type of scan called a PET/CT scan (which uses a special tracer to detect cancer activity) done before, during, and after their cancer treatment
People who were treated with a standard first-line treatment plan for lymphoma, chosen according to accepted medical guidelines and their individual circumstances
People who have complete medical records and follow-up information available

Who may not be able to join:

People who have previously received any cancer treatment before the current lymphoma diagnosis
People who have a history of any other type of cancer
People whose medical records or scan images are incomplete or missing
People who currently have another active cancer at the same time as their lymphoma

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Ruijin Hospital

Registry

ClinicalTrials.gov

Start date

1 June 2013

Est. completion

31 December 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov